Chengdu Yunke Pharmaceutical Co., Ltd.
Chengdu Yunke Pharmaceutical Co., Ltd. was formerly known as Chengdu Institute of Isotope Application Technology, Nuclear Power Institute of China (established in 1992), and was reorganized in July 2001. The company is located in the national high-tech development zone - Chengdu High-tech Development Zone, and its plant area is located in the Southwest Airport Economic Development Zone. It is the Enterprise Technology Center of Sichuan Province and a national high-tech enterprise. The company has a standard plant of 6,000m2, and is the first enterprise in the field of the nuclide drugs of China which pass the GMP certification. The company specializes in the technology research, product development, production and sales, technical consultation and technical services of radiopharmaceuticals. It has the specialized drug development unit, chemical and biological research laboratory, quality control laboratory, radiochemical laboratory, drug clinical observation and treatment center and other related scientific research and development experimental bases, GMP standard plants and sales network throughout the country.
The company is the support unit of the Radiopharmaceutical Engineering Technology Research Center of Chengdu and the Radiopharmaceutical Industry-University-Research Joint Laboratory of Chengdu, and a co-unit of the Isotope Engineering Technology Center of Sichuan Province. The company is the training base for the doctoral and master students in the “nuclear technology and application” program of Nuclear Power Institute of China and has two doctoral supervisors and five master’s supervisors. It has the technological advantages and talent reserves in the preparation of medical radionuclides, R&D of innovative radiopharmaceuticals, medical devices for radiopharmaceutical application, and innovative chemical drugs for bone related diseases.
The company has successfully developed 9 types of radioimmune diagnostic kits and in vivo imaging diagnostic kits, as well as the innovative drug for the treatment of rheumatoid arthritis and bone diseases, technetium [99Tc] methylene diphosphonate injection (trade name: “Yunke”). “Yunke” is one of the radiopharmaceuticals which China has the independent intellectual property rights, and it was awarded the certificate of “National Key New Product”. The company has obtained 11 national invention patents, 3 European and American invention patents, 1 Chinese Patent Excellence Award and 1 Second Prize of the Ministerial Science and Technology Progress Award.
Industrial Layout
